Scarica l'app Stockscreener
5.65
22.80%
1.00
Precedente Chiudi:
$4.65
Aprire:
$4.67
Volume 24 ore:
1.36M
Relative Volume:
10.61
Capitalizzazione di mercato:
$48.82M
Reddito:
$140.46M
Utile/perdita netta:
$-146.34M
Rapporto P/E:
-4.4488
EPS:
-1.27
Flusso di cassa netto:
$-117.73M
1 W Prestazione:
+44.92%
1M Prestazione:
+34.67%
6M Prestazione:
-38.26%
1 anno Prestazione:
-54.36%
Intervallo 1D:
$4.67
$6.90
Intervallo di 1 settimana:
$3.6503
$6.90
Portata 52W:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.65 | 38.45M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.88 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.87 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.52 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
649.17 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.52 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - MSN
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results - simplywall.st
Karyopharm Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics shares rise 1.03% premarket after reporting Q2 earnings. - AInvest
Baird Lowers Karyopharm PT to $25 from $42 Amid Patent Concerns - AInvest
Karyopharm Therapeutics Reports Q2 Loss Amid Revenue ShortfallNews and Statistics - IndexBox
Karyopharm Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks
Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize
Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize
Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN
Karyopharm Therapeutics Sees $1B Peak Revenue Potential in Myelofibrosis by 2026 - AInvest
Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest
Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha
Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Karyopharm Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Q2 EPS Misses Estimate, Revenue Down 11.4% Y/Y - AInvest
Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest
Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Earnings Outlook For Karyopharm Therapeutics - 富途牛牛
Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser
Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingMarket Timing Strategy with Technical Filters - Newser
Karyopharm Therapeutics shares rise 1.78% after-hours following Bicycle Therapeutics' board expansion. - AInvest
Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView
Tick level data insight on Karyopharm Therapeutics Inc. volatilityTechnical Trade Plan with Entry Checklist - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesFree Weekly Potential Breakout Stock List - Newser
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
What data driven models say about Karyopharm Therapeutics Inc.’s futureBuy Strategy Review With Performance Summary - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 - Eastern Progress
Karyopharm Therapeutics Inc. stock prediction for this weekAI Swing Strategy Signal Forecasting System - Newser
Candlestick signals on Karyopharm Therapeutics Inc. stock todayHigh Reward Picks with Tight Risk Control - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersFast Entry Strategy with Price Prediction - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on Au - GuruFocus
Will Karyopharm Therapeutics Inc. stock split in the near futureStock Price Prediction Using AI Tools - Newser
Karyopharm Therapeutics Inc. Sees Spike in Bullish Option FlowPattern Alert With ROI Driven Strategy Shared - beatles.ru
Is Karyopharm Therapeutics Inc. a growth stock or a value stockTriple-digit profit margins - Jammu Links News
Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionUnlock real-time trading signals for gains - Jammu Links News
What makes Karyopharm Therapeutics Inc. stock price move sharplyUnlock powerful portfolio management tools - Jammu Links News
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):